CareDx, Inc. (CDNA)
| Market Cap | 4.19B +385.9% |
| Revenue (ttm) | 497.40M +38.9% |
| Net Income | 128.63M +82.6% |
| EPS | 2.41 +98.4% |
| Shares Out | 52.54M |
| PE Ratio | 33.10 |
| Forward PE | 54.29 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 685,843 |
| Open | 78.54 |
| Previous Close | 81.17 |
| Day's Range | 76.55 - 80.07 |
| 52-Week Range | 15.15 - 90.87 |
| Beta | 2.49 |
| Analysts | Buy |
| Price Target | 94.43 (+18.32%) |
| Earnings Date | Oct 29, 2026 |
About CDNA
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about dist... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for CDNA stock is "Buy." The 12-month stock price target is $94.43, which is an increase of 18.32% from the latest price.
News
CareDx initiated with an Overweight at Piper Sandler
Piper Sandler analyst David Westenberg initiated coverage of CareDx (CDNA) with an Overweight rating and $100 price target The market underestimates the company’s ability to grow beyond annual transpl...
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the award of indu...
CareDx announces third KOAR analysis published in Transplantation
CareDx (CDNA) announced the publication of a new analysis from the Kidney Allograft Outcomes AlloSure Registry, KOAR, a multicenter study, in the journal Transplantation. Key findings include: Patient...
CareDx Announces Third KOAR Analysis Published in Transplantation
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the publication o...
CareDx price target raised to $90 from $46 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on CareDx (CDNA) to $90 from $46 and keeps a Neutral rating on the shares. The firm cites the company’s “robust” Q3 report…
Why Is CareDx Stock (CDNA) Up 18% Today?
CareDx stock was up almost 18% following a strong Q3 earnings report and a price target increase.
CareDx price target raised to $92 from $81 at BTIG
BTIG raised the firm’s price target on CareDx (CDNA) to $92 from $81 and keeps a Buy rating on the shares after its Q3 earnings beat and guidance raise. The…
CareDx price target raised to $99 from $80 at Canaccord
Canaccord raised the firm’s price target on CareDx (CDNA) to $99 from $80 and keeps a Buy rating on the shares. The company reported solid performance in its core transplant…
CareDx Earnings Call Transcript: Q3 2026
Q3 revenue rose 39% YoY to $139 million, testing volume grew 51%, and adjusted EBITDA doubled to $30 million. FY2026 revenue and EBITDA guidance increased as transplant growth, NavDx integration and 2027 pipeline launches advanced.
CareDx Earnings release: Q3 2026
CareDx released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
CareDx Quarterly report: Q3 2026
CareDx has published its Q3 2026 quarterly earnings report on October 29, 2026.
CareDx Slides: Q3 2026
CareDx has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
CareDx reports Q3 GAAP EPS 35c vs 3c last year
Reports Q3 revenue $139M, consensus $121.96M. “We delivered another strong quarter of solid execution, with continued growth in Transplant, progress scaling Specialty Oncology, and important advances ...
CareDx raises FY26 revenue view to $520M-$530M, consensus $495.12M
Previous view $490M-$500M. Raises FY26 adjusted EBITDA view to $90M-$100M from $66M-$78M.
CareDx Announces Third Quarter 2026 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today reported financial results ...
CareDx price target raised to $81 from $74 at BTIG
BTIG analyst Mark Massaro raised the firm’s price target on CareDx (CDNA) to $81 from $74 and keeps a Buy rating on the shares as part of a broader research…
CareDx highlights data featuring AlloSure Kidney at ASN Kidney Week
CareDx (CDNA) highlighted data featuring AlloSure Kidney donor-derived cell-free DNA being presented at the American Society of Nephrology, ASN, Kidney Week 2026, taking place October 22-25 in Denver,...
CareDx Announces New KOAR Data Linking Elevated AlloSure® Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes in Patients with Borderline Rejection or TCMR at ASN Kidney Week 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today highlighted data featuring ...
CareDx price target raised to $80 from $65 at Canaccord
Canaccord raised the firm’s price target on CareDx (CDNA) to $80 from $65 and keeps a Buy rating on the shares. The firm updated its model ahea dof Q3 results…
CareDx to Report Third Quarter 2026 Financial Results on October 29, 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report fi...
CareDx management to meet with Piper Sandler
Meeting to be held in New York on October 2 hosted by Piper Sandler.
CareDx price target raised to $74 from $60 at BTIG
BTIG raised the firm’s price target on CareDx (CDNA) to $74 from $60 and keeps a Buy rating on the shares ater hosting investor talks with its management team. CareDx…